Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston May 12, 2023 10:10am
221 Views
Post# 35445252

RE:70% of TLT patients are CIS...

RE:70% of TLT patients are CIS...Wildbird1 ... Great post and link that confirms the heavy lifting TLT has done so far and how difficult it is to tackle those CIS cases.

You provided a perspective that will justify the interest of a big pharma, without a doubt, given the challenge CIS cases present.

Again, excellent post.  The link is really worth consulting to understand the outstanding job Theralase has done so far.

Hold on to your shares.  Recognition (and so validation) will come.  It's just a question of time.  TLT is doing the right things, in the right order, not cutting corners and respecting the very conservative attitude on the e urology industry.  They don't like splash.  They want data.  Convincing data.  Then, they will adopt.
<< Previous
Bullboard Posts
Next >>